Pipeline/Trials

Our commitment to excellence

Taking on the challenges inherent in today’s cancer treatments isn’t easy…but we’re up for it. We are Athenex—a team of scientists, investigators, and innovators driven by the patients we serve. Our robust investigational pipeline of novel small molecule, biologic, and cellular therapies is focused on both improving outcomes and improving the cancer treatment experience for patients around the world.

Program

Drug candidate

Indication

Pre-clinical

Phase 1

Phase 2

Phase 3

Src Kinase Inhibition

Klisyri® (tirbanibulin ointment)

Actinic keratosis

Orascovery

Angiosarcoma

Oral paclitaxel + encequidar with dostarlimab**

Neoadjuvant breast cancer
(I-SPY 2)

Oral eribulin + encequidar

Solid tumors

Cell Therapy

TCRT-ESO-A2

Multiple tumors

KUR-501 – GD2 autologous CAR-NKT

Neuroblastoma

KUR-502 – CD19 allogeneic CAR-NKT

R/R lymphoma and leukemia

KUR-503 – GPC3 allogeneic CAR-NKT

Hepatocellular Carcinoma

Arginase Deprivation Therapy

PT01

Multiple tumors

Posted pipeline was current on June 28, 2021. Pipeline may not reflect changes in phase of development after June 28, 2021.

* Encequidar is the international nonproprietary name (INN) for HM30181A, our novel P-gp pump inhibitor molecule.
** Collaboration with Quantum Leap Healthcare Collaborative and GlaxoSmithKline.
*** Collaboration with Eli Lilly and Company, makers of ramucirumab.

Clinical Platform

Src Kinase Inhibition

Klisyri® (tirbanibulin ointment)


Actinic keratosis

PHASE 3
(FDA APPROVED)

Clinical Platform

Orascovery

PHASE 2

Oral paclitaxel + encequidar with dostarlimab**


Neoadjuvant breast cancer
(I-SPY 2)

PHASE 2
PHASE 1
PHASE 1

Oral eribulin + encequidar


Solid tumors

PHASE 1

Clinical Platform

Cell Therapy

TCRT-ESO-A2


Multiple tumors

PHASE 1

KUR-501 – GD2 autologous CAR-NKT


Neuroblastoma

PHASE 1

KUR-502 – CD19 allogeneic CAR-NKT


R/R lymphoma and leukemia

PHASE 1

KUR-503 – GPC3 allogeneic CAR-NKT


Hepatocellular Carcinoma

PRE-CLINICAL

Clinical Platform

Arginase Deprivation Therapy

PT01


Multiple tumors

PHASE 1

Posted pipeline was current on June 28, 2021. Pipeline may not reflect changes in phase of development after June 28, 2021.

* Encequidar is the international nonproprietary name (INN) for HM30181A, our novel P-gp pump inhibitor molecule.
** Collaboration with Quantum Leap Healthcare Collaborative and GlaxoSmithKline.
*** Collaboration with Eli Lilly and Company, makers of ramucirumab.